ASTL and neoplasm: These studies position SAS1B as a viable target of an immunotoxin in cancer, with the attending advantages of limited on target/off-tumor effects on normal tissues, and support the study of ADCs for the treatment of SAS1B-positive (SAS1Bpos) tumors.